Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio reports developments from its clinical-stage biopharmaceutical pipeline of Natural Killer T cell modulators for inflammatory, fibrotic and autoimmune diseases. Recurring updates center on GRI-0621, an RARβγ agonist being developed as an oral therapy for idiopathic pulmonary fibrosis, including Phase 2a clinical, biomarker, immune-profiling and gene-expression data.
The company also issues news on GRI-0803 and other type 2 diverse NKT agonist programs, patents covering dNKT agonists and novel compound compositions, its proprietary compound library, financial results, equity financings, Nasdaq compliance matters, reverse stock split actions and conference participation.
GRI Bio (NASDAQ: GRI) reported Q1 2026 results and clinical updates for IPF candidate GRI-0621.
Phase 2a in idiopathic pulmonary fibrosis met its primary safety endpoint, showing zero cough, reduced dyspnea, no weight loss and 61% less diarrhea versus placebo, alongside FVC improvements.
Cash was $11.0 million, with runway into Q2 2027.
GRI Bio (NASDAQ: GRI) received a Notice of Allowance from the United Arab Emirates Patent Office on April 8, 2026, for UAE Patent No. P6000687/2017 titled “Prevention and Treatment of Inflammatory Conditions.”
The allowed claims cover novel type 2 diverse NKT (dNKT) cell agonists and related methods, expanding the company’s global IP protection for its immunomodulatory platform and supporting future regional partnerships, licensing and commercialization in the UAE and MENA region.
GRI Bio (NASDAQ: GRI) said CEO Marc Hertz was featured in a Virtual Investor “What This Means” segment on February 17, 2026. Hertz discussed additional positive Phase 2a data in idiopathic pulmonary fibrosis (IPF), highlighting biomarker improvements tied to fibrosis and lung repair.
The segment is available via the company's virtual investor content library for investors seeking details on the biomarker results and clinical implications.
GRI Bio (NASDAQ: GRI) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually February 10-11, 2026. The company will deliver a live video webcast presentation on Wednesday, February 11, 2026 at 1:00 PM EST, presented by Marc Hertz, PhD.
Registration is available via the company's provided link. The presentation will cover GRI Bio's pipeline and corporate update for investors.
GRI Bio (NASDAQ: GRI) reported year-end $8.2 million in cash and cash equivalents as of December 31, 2025 and raised an additional $6.5 million in January 2026, strengthening the balance sheet to fund operations into Q1 2027. Key clinical highlights include positive Phase 2a topline data for GRI-0621 in idiopathic pulmonary fibrosis, supplemental RNA‑seq and immune phenotype data reinforcing proof‑of‑concept, and advancement of GRI-0803 toward IND‑enabling studies for autoimmune indications.
GRI Bio (NASDAQ: GRI) reported new Phase 2a RNA‑sequencing data for GRI-0621 in idiopathic pulmonary fibrosis (IPF) showing significant differential gene expression across pathways linked to lung injury, myofibroblast activation, extracellular matrix deposition, and alveolar basement membrane and epithelial repair versus placebo.
These gene expression changes align with earlier biomarker and immune phenotype signals—reduced neutrophil activity, increased fibrillar collagen degradation, and lower pro‑fibrotic cytokines—and support a mechanism consistent with fibrosis resolution and alveolar regeneration. The study met its primary safety endpoint, showed multiple secondary signs of disease‑modifying activity, and reported exploratory FVC benefit at 12 weeks.
GRI Bio (NASDAQ: GRI) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,528,775 on January 26, 2026, granting composition-of-matter claims for a distinct class of proprietary compounds.
The patent covers linked molecular structures that form pyrrolidine, piperidine, or azepane ring systems, which the company says are separate from prior patents and strengthen its intellectual property estate. The issuance supports GRI Bio’s platform targeting NKT cell biology and complements its lead program GRI-0621 and a chemistry library of over 500 proprietary compounds.
GRI Bio (NASDAQ: GRI) announced a 1-for-28 reverse stock split, effective 4:01 p.m. ET on January 23, 2026, with post-split trading to begin on a split-adjusted basis on The Nasdaq Capital Market on January 26, 2026 under the ticker GRI and new CUSIP 3622AW502.
The reverse split reduces outstanding shares from ~15,016,434 to ~536,301 and is intended to help the company regain compliance with Nasdaq's minimum bid price requirement. Fractional shares will be paid in cash based on the closing price on January 23, 2026. Proportional adjustments will apply to options, warrants, convertible securities, and incentive plan shares.
GRI Bio (NASDAQ: GRI) reported positive Phase 2a flow cytometry data for GRI-0621 in idiopathic pulmonary fibrosis (IPF). After 12 weeks, treated subjects showed iNKT inhibition, increased TCR expression, higher anti-fibrotic IFN-γ and reductions in IL-4, IL-13, IL-17A, IL-22 and TGF-β in BAL and PBMC samples versus baseline or placebo.
The randomized, double-blind 2:1 study enrolled 35 subjects (4.5mg daily or placebo) with an 8-subject BAL sub-study. The trial met its primary safety/tolerability endpoint and reported exploratory signals of collagen turnover, lung repair and more subjects with no FVC decline at 12 weeks versus standard of care. Company completed a December 2025 public offering and reports stockholders' equity above the Nasdaq $2.5M minimum.
GRI Bio (NASDAQ: GRI) closed a public offering on Dec 12, 2025 of 10,666,667 common shares (or equivalents) with accompanying Series F warrants at a combined public offering price of $0.75 per share and warrant.
Aggregate gross proceeds to the company were approximately $8.0 million before placement agent fees and offering expenses. The Series F warrants are exercisable immediately at $0.75 per share, expire five years after issuance, and could generate approximately $8.0 million additional gross proceeds if fully exercised. H.C. Wainwright acted as exclusive placement agent. The company intends to use net proceeds for product candidate development, working capital and general corporate purposes. The offering was made under an S-1 declared effective by the SEC on Dec 11, 2025.